ATTN: Medical Health Officers and Branch Offices
Public Health Nursing Administrators and Assistant Administrators
Holders of Communicable Disease Control Manuals

Re: Update to Communicable Disease Control Manual, Chapter 2: Immunization
Part 4 – Biological Products & Supporting Documents

Part 4 – Biological Products

Influenza Vaccines

2021/22 Seasonal Influenza Vaccines

- Influenza pages for the 2021/22 season have been revised.
- The eligibility criteria for publicly funded influenza vaccine are unchanged.
- Revisions to the influenza pages include:
  - The vaccine strains contained in the 2021/22 influenza vaccines.
  - The “Intended Use of Influenza Vaccines” table has been revised to include the vaccines for the 2021/22 publicly funded program. The page has a link to the updated Question & Answer Document related to FLUZONE HIGH-DOSE® QUADRIVALENT.
  - New product pages have been added for the 2021/22 influenza season – see below.
  - FLUZONE HIGH-DOSE® QUADRIVALENT vaccine is publicly funded for individuals 65 years of age and older living in long term care, assisted living facilities, and First Nations communities.
  - The dosage of FLUZONE HIGH-DOSE® QUADRIVALENT is 1 dose of 0.7 mL.
  - AFLURIA® TETRA vaccine is not approved for use in those less than 5 years of age.
  - The adverse events content has been revised.

Please remove the following pages:

- 2020/21 Seasonal Influenza Vaccine Eligibility: page 1 dated August 2020
- Safety Issues Applicable to Influenza Vaccines: page 1 dated August 2020
- Intended Use of Influenza Vaccines: page 1 dated December 2020
- FLUMIST® QUADRIVALENT: pages 1-3 dated December 2020
- FLULAVA® TETRA: pages 1 & 2 dated December 2020
• FLUZONE® QUADRIVALENT: pages 1 & 2 dated December 2020
• INFLUSPLIT® TETRA: pages 1 & 2 dated December 2020
• FLUVIRAL®: pages 1 & 2 dated December 2020
• AGRIFLU®: pages 1 & 2 dated December 2020
• FLUAD®: pages 1 & 2 dated December 2020
• FLUZONE® HIGH-DOSE: pages 1 & 2 dated December 2020

Please add the following pages:
• 2021/22 Seasonal Influenza Vaccine Eligibility: page 1 dated August 2021
• Safety Issues Applicable to Influenza Vaccines: page 1 dated August 2021
• Intended Use of Influenza Vaccines: page 1 dated August 2021
• FLUMIST® QUADRIVALENT: pages 1-3 dated August 2021
• AFLURIA® TETRA: pages 1 & 2 dated August 2021
• FLULAVAL® TETRA: pages 1 & 2 dated August 2021
• FLUZONE® QUADRIVALENT: pages 1 & 2 dated August 2021
• FLUZONE® HIGH-DOSE QUADRIVALENT: pages 1 & 2 dated August 2021

Please also remove the Title Page and Table of Contents for Part 4 – Biological Products dated May 2021, and replace with the enclosed updated Title Page and Table of Contents dated August 2021.

Supporting Documents

Latex Content in Vaccines
• AFLURIA® TETRA and FLUZONE® HIGH-DOSE QUADRIVALENT have been added to the list of products that do not contain latex. The following products have been removed from the document as they are not being marketed: AGRIFLU®, FLUVIRAL®, Td POLIO ADSORBED and VAXIGRIP®.

Please remove page number: 1 dated August 2020
Please add page number: 1 dated August 2021
If you have any questions or concerns, please contact Stephanie Meier, Senior Practice Leader, BCCDC (telephone: 604-707-2577 / email: stephanie.meier@bccdc.ca).

Sincerely,

Monika Naus MD MHSc FRCPC FACPM
Medical Director
Communicable Diseases & Immunization Service
BC Centre for Disease Control

pc:  
Provincial Health Officer  
Dr. Bonnie Henry

BC Ministry of Health, Population & Public Health Division:

Dr. Reka Gustafson  
Vice President, Public Health & Wellness, PHSA & Deputy Provincial Health Officer

Brian Sagar  
Senior Director Communicable Disease, Population and Public Health Division

Deputy Provincial Health Officer  
Dr. Martin Lavoie

Bernard Achampong  
Executive Director, Public Health, Planning and Prevention, Population and Public Health Division